UNSPSC 51142312: Nalorphine bromide

This classification denotes a narcotic antagonist with the molecular formula C20H23NO3.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1OLB66508A, chemically known as morphinan-3,6-.alpha.-diol, 17-allyl-7,8-didehydro-4,5-.alpha.-epoxy-, hydrobromide, but more generally known as nalorphine bromide, which bears US NIH Compound Identifier 5486631. European Medicines Agency schedules nalorphine bromide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09141MIG.

Most nations, for tariff purposes, schedule nalorphine bromide under HS 29391900. SMILES: COC1CCC2C3C1O[C@@H]4[C@]35CCN([C@H](C2)[C@@H]5C=C[C@@H]4O)CC=C.BR.

UNSPSC 51142312 Nalorphine bromide is a Commodity code that captures pharmaceutical supply procurements by state and local governments, though recent opportunities posted under this code show limited direct focus on nalorphine itself and instead reflect broader emergency response and pharmacy benefit purchasing. State and local buyers using this code range from county health departments and state health-and-human-services agencies to cooperative purchasing alliances spanning multiple states. The scope of work includes procurement of pharmaceutical products for community health initiatives, emergency response systems, and managed pharmacy benefit programs serving state employees and beneficiaries. Seminole County, Florida issued a competitive IFB in June 2026 for naloxone and drug deactivation systems—1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries to a community health building, requiring vendors to handle shipping and comply with E-Verify and drug-free workplace certification. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers and maintain cGMP and Drug Supply Chain Security Act compliance, with evaluation weighted 75 percent on price competitiveness and 25 percent divided among fixed pricing, administrative fee compliance, and EDI capability.

Recent activity centers on Florida and Minnesota, with broader multistate reach through MMCAP's cooperative purchasing vehicle. Seminole County's IFB closed July 26, 2023, though posted in June 2026, indicating a potential data-source timing lag; the procurement requires unit pricing, workers' compensation and commercial general liability insurance, and noted potential FEMA funding with associated federal compliance obligations. The Texas Health and Human Services Commission issued a Request for Information in April 2026 regarding direct-to-manufacturer prescription programs, seeking vendor experience with direct contracting outside traditional pharmacy benefit manager and group purchasing organization channels, which is exploratory rather than a formal competitive solicitation. MMCAP's RFP closes March 26, 2026, and requires vendors to maintain relationships with at least two of three specified wholesalers, accept a 3 percent administrative fee on all purchases, and carry professional liability coverage of $2 million; the contract term is two years for new vendors with optional extensions. Set-aside designations do not appear in the recent solicitation materials reviewed.